Abbott Laboratories reported solid fourth-quarter and full-year 2025 results, characterized by revenue growth across most segments and double-digit earnings per share expansion, driven by strong performance in Medical Devices and Established Pharmaceuticals. The company also provided a positive financial outlook for 2026, projecting continued organic sales growth and EPS expansion, while strategically positioning itself for future growth through an acquisition in cancer diagnostics.
Full-year 2025 adjusted diluted EPS of $5.15 reflects growth of 10 percent.
positiveFourth-quarter adjusted diluted EPS of $1.50 reflects growth of 12 percent.
positiveMedical Devices sales increased 12.3% on a reported basis and 10.4% on an organic basis in Q4.
positiveEstablished Pharmaceuticals sales increased 9.0% on a reported basis and 7.0% on an organic basis in Q4.
positiveAbbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%.
positiveAbbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, reflecting 10 percent growth at the midpoint.
positiveWorldwide Nutrition sales decreased 8.9% on a reported basis and 9.1% on an organic basis in Q4, reflecting lower sales volumes and strategic price actions.
attentionGlobal Diagnostics sales decreased 2.5% on a reported basis and 3.6% on an organic basis in Q4, with COVID-19 testing sales declining significantly.
attentionFull-year 2025 Diagnostics sales decreased 4.3% on a reported basis and 4.5% on an organic basis.
attentionThe acquisition of Exact Sciences, while strategic, represents a significant move into a new market and will require integration and execution.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total |
|---|---|---|---|---|
Medical Devices | $5675000.0B | $5053000.0B | +12.3% | 49.5% |
Diagnostics | $2457000.0B | $2520000.0B | -2.5% | 21.5% |
Nutrition | $1940000.0B | $2130000.0B | -8.9% | 16.9% |
Established Pharmaceuticals | $1382000.0B | $1268000.0B | +9.0% | 12.1% |
| Total Revenue | $11454000.0B | — | — | 100.0% |
Segment performance shows business unit health and growth drivers.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
In 2025, we expanded margins and achieved double-digit earnings per share growth, our new product pipeline was highly productive, and we took important strategic steps to shape the company for the future.
We're well positioned for accelerating growth in 2026.
We expanded our leadership in Electrophysiology with two significant regulatory approvals.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.